Discovery PET/CT – The clinical choice | GE Healthcare

Oncology dominates the utilization of PET scans. According to AMR US & Europe PET/CT procedure data for 2011, approximately 95% of all PET/CT scans are used in the area of diagnosis, staging & therapy assessment in oncology. In addition, 99% of scans performed use low-medium count rate isotopes such as F18 FDG. The new BGO systems such as the Discovery* 600/610 PET/CT combine high sensitivity and sharp resolution to deliver high image quality and lesion detection at low dose. In this video, physicians at Cancer Treatment Centers of America (CTCA) in Tulsa discuss their experience with the Discovery 600 PET/CT system. They discuss how the excellent staging capability and improved resolution has probably resulted in additional referrals and is making a clinical impact by enabling detection of early metastases. Discovery PET/CT with the new BGO … the clinical choice.
*Trademark of General Electric Company #GEHealthcare #GeneralElectric

Subscribe to GE Healthcare:

Learn more about GE Healthcare

About GE Healthcare:
As a leading global medical technology and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform.

With over 100 years of healthcare industry experience and around 50,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.

We embrace a culture of respect, transparency, integrity and diversity.

Discovery PET/CT – The clinical choice | GE Healthcare


Leave a Reply

Your email address will not be published. Required fields are marked *

Send message via your Messenger App